Publications
Cosman F, Krege, J; Looker A; Schousboe J; Fan B; Isfahani N; Shepherd J; Krohn k; Steiger P; Wilson K; Genant H “Spine Fracture Prevalence in a Nationally Representative Sample of US Women and Men Aged ≥40 years: Results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014 Online Osteoporosis International 2017
Saag K, Agnusdei D, Hans D, Kohlmeier L, Krohn k, Leib E, MacLaughlin E, Alam J, Simonelli C, Taylor K, Marcus R “Trabecular Bone Score in Patients with Chronic Glucocorticoid Induced Osteoporosis Treated with Alendronate or Teriparatide” Published on line: Arthritis & Rheumatology 2016 DOI 10.1002/art.39726E
Bhandari M, Jin L, See K, Burge R, Gilchrist N, Witvrouw R, Krohn kD, Warner MR, Ahmad QI, Mitlak B. “Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial” Clin Orthop Relat Res. 2016 May;474(5):1234-44. doi: 10.1007/s11999-015-4669-z. Epub 2016 Mar 1. PMID: 26932738
Krege J, Kendler D, Krohn k, Genant H, Alam J, Berclaz P, Coffey B, Loghin C “Relationship Between Vertebral Fracture Burden, Height Loss, and Pulmonary Function in Postmenopausal Women With Osteoporosis“ Journal of Clinical Densitometry (online) DOI: http://dx.doi.org/10.1016/j.jocd.2015.02.004
Kleerekoper M, Greenspan S, Lewiecki M, Miller P, Kendler D, Maricic M, Keaveny T, Kopperdahl D, Ruff V, Wan X, Janos B, Krohn k “Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength” J Bone Joint Surg Am. 2014;96:e90(1-9)
Solomon D, Johnston S, Boytsov N, McMorrow D, Lane J, Krohn k “Osteoporosis Medication Use After Hip Fracture in US Patients between 2002 and 2011″ J Bone Miner Res. 2014 Sept;29(9):1929-1937.
Zhao Y, Johnston SS, Smith DM, McMorrow D, Krege J, Krohn k “Association between teriparatide adherence and healthcare utilization and costs among hip fracture patients in the United States” Bone, 2014;60:221-226.
Zhao Y, Johnston SS, Smith DM, McMorrow D, Krohn k, Krege J “Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients” Osteoporosis International 2013 Sept; Volume 24(9): 2525-2533
Salacinski A, Krohn k, Lewis S, Holland M, Ireland K, Marchetti G.
“The effects of group cycling on gait and pain-related disability in individuals with mild-to-moderate knee osteoarthritis: a randomized controlled trial” J Orthop Sports Phys Ther. 2012 Dec;42(12):985-95
Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn kD, Krege JH. “Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.” J Bone Miner Res. 2013 Jun;28(6):1328-36
Silverman S, Miller P, Sebba A, Weitz M, Wan X, Alam J, Masica D, Taylor KA, Ruff VA, Krohn k. “The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results” Osteoporos Int 2013 Aug;24(8):2309-17
Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn k. “Femoral strength in osteoporotic women treated with teriparatide or alendronate”. Bone. 2012 Jan;50(1):165-70.
Gold DT, Weinstein DL, Pohl G, Krohn kD, Chen Y, Meadows ES. “Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational Study”. J Osteoporos. 2011;2011:314970.
Tamariz L, Uribe CL, Luo J, Hanna JW, Ball DE, Krohn k, Meadows ES. “Persistence with biologic therapies in the Medicare coverage gap”. Am J Manag Care. 2011 Nov;17(11):753-9.
Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn k, GarcÃa-Hernández PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC. “Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures.” J Bone Miner Res. 2010 Feb;25(2):404-14.
Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn k, Warner MR “Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.”Arthritis Rheum. 2009 Nov;60(11):3346-3355.
Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, and Krohn k. “Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.” J Rheumatol. 2010 Jan;37(1):141-148
Watts N, Miller P, Kohlmeier L, Sebba A, Chen P, Wong M and Krohn k: “Vertebral Fracture Risk is Reduced for Women Who Lose Femoral Neck Bone Mineral Density during Teriparatide Treatment” Journal of Bone and Mineral Research 2009 Jun;24(6):1125-1131.
Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn k, See K, Warner MR “Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.” Osteoporos Int. 2009 Dec;20(12):2095-2104.
Losada BR, Zanchetta JR, Zerbini C, Molina JF, De la Peña P, Liu CC, Smith RB, Nino AJ, Krohn k, Warner MR. “Active comparator trial of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: results from the hispanic and non-hispanic cohorts”. J Clin Densitom 2009, 12(1) 63-70
Chen P, Miller P, Binkley N, Kendler D, Wong M and Krohn k “Use of Lowest Individual Lumbar Spine BMD T- Score for Diagnosis of Osteoporosis and for Prediction of Prevalent and Incident Vertebral Fractures” J Clin Densitom 2008, 11(4) 525-531
Krohn kD, Fitzgerald GK “Non-pharmacologic, non-surgical management of knee osteoarthritis” J of Musculoskeletal Medicine 2006;23:460-443
Krohn kD, Fitzgerald GK “Exercise for management of knee osteoarthritis” J of Musculoskeletal Medicine 2006; 23:505-509
Krohn kD “Footwear alterations and bracing as treatments for knee osteoarthritis” Current Opinions in Rheumatology 17:653-656, September 2005
Filner JJ, Krohn kD, Lapidus JA, Becker TM: “Risk factors for osteoporosis in Alaska Native women: a cross- sectional survey” Alaska Medicine 2002 Jan-Mar;44(1) pp 8-13
Hungerford D, Apple D, DiNubile N, du Souich P, Hungerford M, Krohn k, Schenck R, Verbruggen A: “The Role of Chondroitin Sulfate in the Management of Osteoarthritis” Orthopedics Today, June 2003
Krohn k ” Effective OA Bracing Hinges on Patient Selection” Biomechanics, 6(7): pp. 45-47, 1999
Deodhar AA, Bruce MG, Krohn kD, Bennett RM: “A Case of Secondary Sjogren’s Syndrome with a Swollen Thigh.” Annals of Rheumatic Diseases, 56: pp. 162-164, 1997.
Kushner DM, Braunstein EM, Buckwalter KA, Krohn k, White HA: “Carpal Instability in Rheumatoid Arthritis.” Canadian Association of Radiologists Journal, 44(4): pp. 291-295, 1993
Tracy T, Krohn D, Jones D, Bradley J, Hall S and Brater D: “The Effects of a Salicylate, Ibuprofen and Naproxen on the Disposition of Methotrexate in Patients with Rheumatoid Arthritis.” European Journal of Clinical Pharmacology 42, pp. 121-125, 1992.
Krohn k, Brandt K, Braunstein E and Mathews V: “Symphalangism: Association with Osteoarthritis.” Journal of Rheumatology 16(7), pp. 977-982, 1989.
Krohn k, Slowman S, and Leapman S: “Cocaine and Acute Rhabdomyolysis” (Letter). Annals of Internal Medicine p 639, April 1988.
Kenik J, Krohn k, Kelly R, et al: “Transverse Myelitis and Optic Neuritis in a Patient with SLE, a Case Report with MRI Findings.” Arthritis and Rheumatism 30(8), pp. 947-950, 1987.
Abstracts
Kellier-Steele N, Krohn k, Midkiff K, Harris D, Andrews E “Post-Marketing Case Series Study of Adult Osteosarcoma and For(s)teo: Study Update from the First 12 years” (ISCD Meeting Galway, Ireland 2016)
Krohn k, Kellier-Steele N, Gilsenan A, Harding A, Andrews E “For(s)teo Voluntary Patient Registry: 6-Year Progress on a Prospective Osteosarcoma Surveillance Study” (ISCD Meeting Galway, Ireland 2016)
Saag K, Agnusdei D, Hans D, Kohlmeier L, Krohn k, Leib E, MacLaughlin E, See K, Simonelli C, Taylor K, Marcus R “Trabecular Bone Score In Patients With Chronic Glucocorticoid Osteoporosis Treated With Alendronate Or Teriparatide” (IOF ESCEO Meeting Milan, Italy 2015)
Bhandari M, Swiontkowski M, Jin L, See K, Burge R, Krohn k, Warner M, Ahmad Q, Mitlak B
“The Effect of Teriparatide on Femoral Neck Fracture Healing in Men and Postmenopausal Women” (2015 Orthopaedic Research Society meeting Las Vegas)
Dore R, Saag R, Valenzuela G, He Q, Taylor K, Alam J, Krohn k “Effect of Teriparatide in Patients with Osteoporosis and Rheumatoid Arthritis” (2014 ACR meeting Boston)
Valenzuela G, Yim D, Beall D, Gordon M, Alam J, Krege J, Krohn k “Effect of Teriparatide in Patients with Osteoporosis with Prior Vertebral Fracture” (2014 ACR meeting Boston)
Krege J, Kendler D, Krohn k, Genant H, Berclaz P, Loghin C: “Relationship of Spine Fracture Burden to Reduced Lung Volume in Postmenopausal Women With Osteoporosis” (2014 ASBMR meeting Houston)
Robins D, Leder B, Krohn k, Alam J, Murphy H, Chiang A, Krege J: “Very Early Responses of Biochemical Markers of Bone Turnover to Teriparatide” (2014 ASBMR meeting Houston)
Krohn k, Kellier N, Masica D, Gilsenan A, Harding A, Andrews E: “Post-marketing Case Series Study Of Adult Osteosarcoma and For(s)teo: Study Finding from the First 9 Years” (2014 ISCD/IOF meeting Orlando)
Krohn k, Kellier N, Masica D, Gilsenan A, Harding A, Andrews E: “Forteo Voluntary Patient Registry: 4-Year Progress on a Prospective Osteosarcoma Surveillance Study” (2014 ISCD/IOF meeting Orlando)
Kellier N, Krohn k , Gilsenan A, Harris D, Andrews E, Masica D: “Forteo Voluntary Patient Registry: 3-Year Progress on a Prospective Osteosarcoma Surveillance Study” (2013 ASBMR meeting Baltimore)
Johnston S, Zhao Y, McMorrow D, Krege J, Krohn k: “Unmet Need for Osteoporosis Treatment in Real World Kyphoplasty/Vertebroplasty Patients” (2013 NOF meeting Chicago)
Johnston S, Zhao Y, McMorrow D, Krege J, Krohn k: “Lack of Osteoporosis Treatment in Real World Hip Fracture Patients” (2012 ASBMR meeting Minneapolis)
Keaveny T, Kopperdahl D, Ruff V, Wan X, Krohn k: “Increases in Both Vertebral and Femoral Strength in Postmenopausal Osteoporotic Women after 18 months of Treatment with Teriparatide” (2011 ASBMR Meeting, San Diego)
Chen P, Gomberg B, Westmore M, Krohn k, Sato M: “Teriparatide Improves Trabecular Architecture as Measured by µCT at Simulated in Vivo Resolution in the Femoral Neck of Ovariectomized Monkeys” (2008 ASBMR Meeting, Montreal)
Taylor K, Gold D, Miller P, Chen P, Wong M, Krohn k: “Teriparatide Therapy in a Community Setting: Persistence and Use of Other Osteoporosis Medications in DANCE” (2008 ASBMR Meeting, Montreal)
Saag K, Zanchetta J, Devogelaer J-P, Adler R, See K, Dalsky G, Krohn k, Krege K, Warner M: “Teriparatide versus Alendronate for Treatment of Glucocorticoid-Induced Osteoporosis: 36-month Results” (2008 ASBMR Meeting, Montreal), (2008 ACR Meeting, San Francisco)
Watts N, Miller P, Marcus R, Chen P, Arsenault J, and Krohn k: “Vertebral Fracture Risk is Reduced for Women Who Lose Femoral Neck Bone Mineral Density during Teriparatide Treatment” (2008 ISCD Meeting, San Francisco), (2008 ENDO Society Meeting, San Francisco)
Krohn k, Adler RA, Devogelaer JP, Recknor C, See K, Wong M, and Agnusdei D: “BMD Response to Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-Induced Osteoporosis” (2007 GIO-5th International Congress, Naples, Italy)
Valenzuela G, Miller P, Rana A, Wong M, Taylor K, and Krohn k: “Monitoring Bone Mineral Density during the Course of Teriparatide Therapy in a Community Setting” (2007 American College of Rheumatology-71st Annual Scientific Meeting, Boston), (2007 ASBMR-29th Annual Meeting, Honolulu)
Keaveny T, Hoffmann P, Kopperdahl D, Donley D, Krohn k, Glass E, and Mitlak B: “Comparison of the Effects of Teriparatide and Alendronate on Parameters of Total Hip Strength as Assessed by Finite Element Analysis: Results from the Forteo and Alendronate Comparison Trial” (2007 ASBMR-29th Annual Meeting, Honolulu)
Krohn k, Adler RA, Devogelaer JP, Recknor C, See K, and Wong M: “Effects of Glucocorticoid Dose on the BMD Response to Teriparatide or Alendronate Therapy” (2007 ASBMR-Targeting Bone Remodeling for the Treatment of Osteoporosis, Washington D.C.)
Krohn k, Sebba A, Sierra-Zorita R, Miller P, Chen P, Taylor K, and Wong M: “The Direct Assessment of Nonvertebral Fracture in Community Experience (DANCE) Study: Baseline Demographics and Reasons for Initiating Teriparatide Therapy” (2007 American College of Rheumatology-71st Annual Scientific Meeting, Boston)
Krohn k, Adler RA, Devogelaer JP, Recknor C, See K, Wong M, and Agnusdei D: “BMD Response to Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-Induced Osteoporosis” (2007 GIO – 5th International Congress, Naples, Italy)
Recknor C, Adler RA, Casas N, Devogelaer JP, See K, Wong M, and Krohn k: “BMD Response to Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-Induced Osteoporosis” (2007 American College of Rheumatology-71st Annual Scientific Meeting, Boston)
Silvestri S, See K, Saag K, Devogelaer JP, Dalsky G, Taylor K, and Krohn k: “Characteristics of Subjects with Incident Vertebral Fractures During a Trial of Teriparatide versus Alendronate in the Treatment of Glucocorticoid- Induced Osteoporosis (2007 GIO-5th International Congress, Naples, Italy)
Binkley N, Recker R, Holst A, Walliser J, Lips P, Pfeifer M, Krohn k, Liu M, Wehren L, and Papanicolaou D: “Effects of Vitamin D3 8300 IU per Week in Elderly Subjects with Vitamin D Insufficiency: Effects on Serum 25- (OH) D Level (2007 NOF Meeting, Washington DC)
Lips P, Pfeifer M, Walliser J, Holst A, Binkley N, Recker R, Krohn k, Liu M, Cohn D, Wehren L, and Papanicolaou D: “Effects of Vitamin D3 8300 IU per Week on Body Sway in Elderly Subjects with Vitamin D Insufficiency” (2007 NOF Meeting, Washington DC)
Losada B, Zanchetta JR, Zerbini C, Molina JF, De La Pena P, Liu C, Glass EV, Nino A, Krohn k, and Warner M: “Active Comparator Trial of Teriparatide versus Alendronate in the Treatment of Glucocorticoid-Induced Osteoporosis: Results from the Hispanic Patient Cohortactive Comparator Trial of Teriparatide versus Alendronate in the Treatment of Glucocorticoid-Induced Osteoporosis: Results from the Hispanic Patient Cohort” (2007 SIBOMM 7th Congreso, Santiago, Chile)
Sebba A, Sierra-Zorita R, Miller P, Chen P, Taylor K, Wong M, and Krohn k: “The Direct Assessment of Nonvertebral Fracture in Community Experience (DANCE) Study: Baseline demographics and Reasons for Initiating Teriparatide Therapy” (2007 ASBMR-29th Annual Meeting, Honolulu)
Taylor K, Gold D, Silverman S, Chen P, Wong M, and Krohn k: “Persistence with TPTD Therapy Among Participants in the DANCE Trial” (2007 ASBMR-29th Annual Meeting, Honolulu)
Chen P, Miller P, Binkley N, Wong M, and Krohn k: “Use of Lowest Individual Lumbar Spine T-score
For Diagnosis of Osteoporosis and for Prediction of Prevalent and Incident Vertebral Fractures” (2007 ISCD Meeting, Tampa)
Varma V, Smolensky H, Culig C, Hunter K and Krohn k: “Screening for Low Bone Density with Heel Ultrasound in the Developmentally Disabled: Correlation with Central DXA” (2006 ISCD Meeting, San Diego)
Krohn k, Smolensky H, Culig C, and Hunter K: “Screening for Low Bone Density with Heel Ultrasound in the Developmentally Disabled” (2004 ISCD Meeting, Miami)
Krohn k, Hall R, Burkhart E, Pearson J, and Pifalo W: “Impact of a Multidisciplinary Osteoporosis Education and Exercise Program in Postmenopausal Women” (2003 ACR Meeting in Orlando and 2004 ISCD meeting, Miami)
Allen E, Yates A, Walczyk J, Buttles S, and Krohn k: “Valgus Bracing for Isolated Medial Compartment Osteoarthritis of the Knee” (2000 ACR Meeting , Philadelphia)
Krohn k, Yates A, Walczyk J, Buttles S, and Berkowitz J: “Valgus Bracing for Isolated Medial Compartment Osteoarthritis of the Knee” (1998 ACR Meeting, San Diego, CA)
Krohn k, Bonafede P, Weirich S, Teisher J, and Schoepflin G: “Oregon Chapter Arthritis Foundation Health Insurance Survey.” (1997 ACR Meeting, Washington DC).
Deodhar A, Krohn k, Bennett R, Wheeler D, and Orwoll E: “Hand Bone Density in Rheumatoid Arthritis” (1997 ACR Meeting, Washington DC).
Krohn k, Tracy T, Jones D, Bradley J, Hall S, and Brater D: “The Effects of a Salicylate, Ibuprofen and Naproxen on the Disposition of Methotrexate in Patients with Rheumatoid Arthritis.” (1989 ACR Meeting, Seattle, WA)
Book Chapters
Allen M, Krohn k: “Skeletal Imaging” Basic and Applied Bone Biology Elsevier Academic Press 2014 Edited by David Burr and Matthew Allen pp. 93-113
Krohn k, Bennett R: “Drug-Induced Autoimmune Disorders.” Immunology and Allergy Clinics of North America 18 (4), pp. 897-909, November 1998
Krohn k: “Pre-operative Bone Health Assessment and the Potential use of Systemic Osteoporosis Drugs in Select
Patients Undergoing Elective Spine Fusion Surgery” AOSpine Textbook (In Print)
Lectures
SunHeath La Loma Village: Bone Health
